IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 201-225 out of 1341.

<< < 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 > >>

Public Release: 5-May-2016
JCI Insight
Multiplexed immunofluorescence reveals protein expression alterations in breast cancer
A new study in JCI Insight reports the use of a multiplexed immunostaining platform to examine the protein expression within breast tumors.
National Institutes of Health, National Brain Tumor Society, GE Healthcare, GE Global Research Center

Contact: Corinne Williams
press_releases@the-jci.org
JCI Journals

Public Release: 5-May-2016
Cell Reports
Antibody appears to attack cancer cells, leaving other cells unscathed
A research team from Duke Health has developed an antibody from the body's own immune system that preferentially attacks cancer cells. The antibody works by targeting a natural defense mechanism that cancer tumors exploit. Cells in the body essentially use a home security system that relies on certain proteins to protect the cell surface and keep it safe. These proteins help the cell avoid injury and even death from unwanted activation of the immune system.
LUNGevity Foundation, US Department of Defense, National Institutes of Health, Duke Translational Research Institute

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center

Public Release: 5-May-2016
Cell
Lung tumors hijack metabolic processes in the liver, UCI study finds
University of California, Irvine scientists who study how circadian rhythms -- our own body clocks -- control liver function have discovered that cancerous lung tumors can hijack this process and profoundly alter metabolism. Their research, published online in Cell, is the first showing that lung adenocarcinoma can affect the body clock's sway over lipid metabolism and sensitivity to insulin and glucose.
National Institutes of Health, Merieux Research Grant, University of California Irvine's Chao Family Comprehensive Cancer Center

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine

Public Release: 5-May-2016
JCI Insight
Treatment with Alk5 inhibitor improves tumor uptake of imaging agents
In this issue of JCI Insight, Heike Daldrup-Link of Stanford University and colleagues demonstrate that pre-treatment with an activin-like kinase 5 (Alk5) inhibitor enhances tumor-specific delivery of the contrast agent ferumoxytol.
NIH/National Cancer Institute, Department of Defense Breast Cancer Research Program Era of Hope Scholar Expansion Award, Susan G. Komen Foundation, Stand Up To Cancer - Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research

Contact: Corinne Williams
press_releases@the-jci.org
JCI Journals

Public Release: 4-May-2016
JAMA Surgery
Readability of online health information for patients with pancreatic cancer
Online information on pancreatic cancer overestimates the reading ability of the overall population and lacks accurate information about alternative therapy, according to a study published online by JAMA Surgery.

Contact: Kelly Lawman
klawman@bidmc.harvard.edu
The JAMA Network Journals

Public Release: 4-May-2016
BJU International
Patient-physician communication is critical for prostate cancer survivors' health
For prostate cancer patients who had their prostates surgically removed, patient-physician communication was key for helping them cope with their disease and for improving their health-related quality of life.

Contact: Penny Smith
sciencenewsroom@wiley.com
44-012-437-70448
Wiley

Public Release: 4-May-2016
British Journal of Surgery
Ovary removal may increase the risk of colorectal cancer
Colorectal cancer may rise in women who have their ovaries removed, according to new research.

Contact: Penny Smith
sciencenewsroom@wiley.com
44-012-437-70448
Wiley

Public Release: 4-May-2016
Otolaryngology-Head and Neck Surgery
Discovery of cancer gene may predict survival in patients with mouth cancers
A newly discovered tumor gene may help to predict survival outcomes in patients with cancer of the mouth and tongue. If the gene is expressed (turned on), patients are 4.6 times more likely to die at any given time. The finding could help guide treatment, Loyola University Chicago researchers say.

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System

Public Release: 4-May-2016
Acta Obstetricia et Gynecologica Scandinavica
Medical conditions are more common in women who are sexually abused
Researchers have found that a variety of conditions are more common in women before and after sexual assault.

Contact: Penny Smith
sciencenewsroom@wiley.com
44-012-437-70448
Wiley

Public Release: 4-May-2016
Oncotarget
Clinical study suggests the origin of glioblastoma subtypes
Researchers at University of California San Diego School of Medicine have demonstrated that distinct types of glioblastoma, the most common form of brain cancer in adults, tend to develop in different regions of the brain. This finding provides an explanation for how the same cancer-causing mutation can give rise to different types of brain malignancies.
Doris Duke Charitable Foundation, Sontag Foundation, Burroughs Wellcome Fund, Forbeck Foundation and Kimmel Foundation

Contact: Jackie Carr
jcarr@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 4-May-2016
Journal of Neuroscience
TSRI scientists find root cause of appetite loss during illness
Loss of appetite during illness is common and potentially debilitating; in cancer patients, especially, it can even shorten lifespan. Scientists at The Scripps Research Institute have discovered how an immune system molecule hijacks a brain circuit and reduces appetite -- research pointing to potential targets for treating appetite loss and restoring patient strength.
National Institutes of Health

Contact: Madeline McCurry-Schmidt
madms@scripps.edu
858-784-9254
Scripps Research Institute

Public Release: 4-May-2016
New England Journal of Medicine
New England Journal of Medicine letter calls prostate cancer screening guidelines into question
Researchers from NewYork-Presbyterian and Weill Cornell Medicine discuss their findings related to PSA screening in this week's New England Journal of Medicine and urge reconsideration of prostate cancer screening after finding critical flaw in landmark study.

Contact: Dominique Grignetti
dmg9030@nyp.org
212-821-0676
NewYork-Presbyterian/Weill Cornell Medical Center

Public Release: 4-May-2016
Gastroenterology
Findings light the way for new treatments in colitis, colon cancer
Oklahoma Medical Research Foundation scientist Lijun Xia, M.D., Ph.D., has discovered that certain sugars produced by the body play an important role in the development of colitis and, ultimately, colon cancer. The new finding could potentially lead to therapies for ulcerative colitis, Crohn's disease and colon cancer.
National Institutes of Health, Oklahoma Center for for Adult Stem Cell Research, University of Oklahoma/Stephenson Cancer Center, Crohn's and Colitis Foundation of America

Contact: Shari Hawkins
shari-hawkins@omrf.org
405-271-8537
Oklahoma Medical Research Foundation

Public Release: 3-May-2016
Nature Genetics
Scientists double number of known genetic risk factors for endometrial cancer
An international collaboration of researchers has identified five new gene regions that increase a woman's risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Cancer Research UK

Contact: Craig Brierley
craig.brierley@admin.cam.ac.uk
44-012-237-66205
University of Cambridge

Public Release: 3-May-2016
JAMA
Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after four months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.

Contact: Pascal Hammel, M.D.
pascal.hammel@aphp.fr
The JAMA Network Journals

Public Release: 3-May-2016
EMBO Reports
Herbal remedies are an overlooked global health hazard
Scientists raise are raising awareness that long-term use of herbal remedies is no guarantee of their safety. Herbal remedies are an overlooked global hazard.

Contact: Dipali Pathak
pathak@bcm.edu
713-798-4710
Baylor College of Medicine

Public Release: 3-May-2016
Trends in Genetics
Autism and cancer share a remarkable number of risk genes in common
Autism and cancer share more than 40 risk genes, suggesting that common mechanisms underlying the functions of some of these genes could conceivably be leveraged to develop therapies not just for cancer but for autism as well, an extensive assessment by researchers with the UC Davis MIND Institute and Comprehensive Cancer Center has found.

Contact: Phyllis K. Brown
pkbrown@ucdavis.edu
916-734-9023
University of California - Davis Health System

Public Release: 3-May-2016
Neurosurgical Focus
Barrow researchers prove utility of imaging tool in surgeon's hand
Barrow researchers prove the utility of new brain tumor imaging tool in the surgeon's hand.

Contact: Lynne Reaves
602-406-4734
St. Joseph's Hospital and Medical Center

Public Release: 3-May-2016
Oncogene
Research points to a new treatment for pancreatic cancer
Researchers have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis, pointing to a potential new treatment using drugs previously developed for atherosclerosis.
National Institutes of Health, NIH/National Cancer Institute

Contact: emil venere
venere@purdue.edu
765-494-4709
Purdue University

Public Release: 2-May-2016
Nature Methods
Current cancer drug discovery method flawed: Study
The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods. The findings cast doubt on methods used by the entire scientific enterprise and pharmaceutical industry to discover new cancer drugs. The researchers have developed a new metric to evaluate a compound's effect on cell proliferation -- called the DIP (drug-induced proliferation) rate -- that overcomes the flawed bias in the traditional method.
Uniting Against Lung Cancer, National Library of Medicine, NIH/National Cancer Institute, NIH/National Center for Advancing Translational Sciences

Contact: Leigh MacMillan
leigh.macmillan@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center

Public Release: 2-May-2016
Journal of the National Cancer Institute
Elevated bladder cancer risk in New England and arsenic in drinking water
A new study has found that drinking water from private wells, particularly dug wells established during the first half of the 20th century, may have contributed to the elevated risk of bladder cancer that has been observed in Maine, New Hampshire, and Vermont for over 50 years.
NIH/National Cancer Institute

Contact: NCI press office
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute

Public Release: 2-May-2016
Cancer Research
Two known chemotherapy agents effectively target breast cancer stem cells
Two existing chemotherapy drugs appear to be a powerful pair in targeting errant stem cells that are making breast cancer and enabling its spread and recurrence, scientists report.
National Cancer Institute, Department of Defense

Contact: Toni Baker
tbaker@augusta.edu
706-721-4421
Medical College of Georgia at Augusta University

Public Release: 2-May-2016
Cell
UTSW identifies new function of genes linked to Fanconi anemia and certain types of cancer
Researchers from UT Southwestern Medical Center have identified an important new function of genes in the Fanconi anemia pathway -- a finding that could have implications for development of new therapies to treat this disorder and some cancers.

Contact: Debbie Bolles
debbie.bolles@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 2-May-2016
Nature Cell Biology
Hormel Institute's Hinchcliffe leads groundbreaking cancer research study
A recent research study at The Hormel Institute, University of Minnesota is providing insight into the regulation of chromosome segregation and the mechanisms used by cells to prevent them from forming tumors.
'Paint the Town Pink'' initiative, US Department of Defensem, National Institutes of Health

Contact: Mandie Siems
msiems@hi.umn.edu
507-437-9602
University of Minnesota

Public Release: 2-May-2016
Cancer
Cognitive-behavioral therapy may help reduce memory problems in cancer survivors who have received chemotherapy
A new analysis indicates that a type of psychotherapy delivered by videoconference may help prevent some of the long-term memory issues caused by chemotherapy

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Showing releases 201-225 out of 1341.

<< < 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 > >>

  Search News Releases

     

 

EurekAlert!